Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger.

Weina Jin,Qinghua Li,Yani Lin,Ying Lu,Huawen Li,Lihong Wang,Ronghua Hu,Li Ma,Jianxiang Wang,Tianxiang Pang
DOI: https://doi.org/10.1016/j.canlet.2011.04.016
IF: 9.756
2011-01-01
Cancer Letters
Abstract:The present study was undertaken to estimate the therapeutic benefit to down-regulate the Na+/H+ exchanger 1 (NHE1) for reversing chemoresistance of BCR-ABL-positive leukemia patient cells and cell lines. As a result, after treatment with specific NHE1 inhibitor Cariporide or high K+ buffer to decrease intracellular pH (pHi), cells from relapsed patients exhibited decreased Pgp level, enhanced Rhodamine123 and drug accumulation, decreased colony-forming ability and the modulations of mitogen-activated protein kinases (MAPKs) activities. Furthermore, we used BCR-ABL-positive cell line K562 and its resistant counterparts K562/DOX and K562/G01 cell lines for further study. Together, these findings suggest that Pgp may be associated with the reversal of drug resistance in BCR-ABL-positive leukemia patients and cell lines by the inhibition of NHE1 though MAPK pathways.
What problem does this paper attempt to address?